Raymond James Financial’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Raymond James Financial’s Portfolio EPRX Stock Details EPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$477K	Sell	52,439 -1,064	-2%	-$7.57K	﹤0.01%	4584
2026 Q2	$354K	Buy	53,503 +2,943	+6%	+$20.3K	﹤0.01%	4729
2026 Q1	$366K	Sell	50,560 -2,412	-5%	-$19.4K	﹤0.01%	4554
2025 Q4	$400K	Buy	52,972 +19,599	+59%	+$121K	﹤0.01%	4410
2025 Q3	$197K	Buy	33,373 +21,161	+173%	+$115K	﹤0.01%	4626
2025 Q2	$70.3K	Buy	12,212 +1,079	+10%	+$4.14K	﹤0.01%	5037
2025 Q1	$36.5K	Sell	11,133 -480	-4%	-$1.66K	﹤0.01%	4667
2024 Q4	$36.8K	Buy	+11,613	New	+$34.4K	﹤0.01%	4651

Other funds holding EPRX

Beutel, Goodman & Co Toronto, Ontario, Canada $12.7B AUM 12.76% 1-Year Est. Return

Affinity Asset Advisors New York $2.46B AUM 196.28% 1-Year Est. Return

Scotia Capital Toronto, Ontario, Canada $28.7B AUM 25.13% 1-Year Est. Return

Vivo Capital Palo Alto, California $909M AUM 385.65% 1-Year Est. Return

Picton Mahoney Asset Management Toronto, Ontario, Canada $14.8B AUM 38.11% 1-Year Est. Return

Aisling Capital Management New York $299M AUM 39.78% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

CIBC World Market Toronto, Ontario, Canada $61.4B AUM 32.2% 1-Year Est. Return

F.L. Putnam Investment Management Lynnfield, Massachusetts $9.33B AUM 30.52% 1-Year Est. Return

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Raymond James Financial's EPRX Position: Q3 2026 in Review

Raymond James Financial reduced its Eupraxia Pharmaceuticals (EPRX) stake by 2% in Q3 2026, selling an estimated $7.57K and leaving 52,439 shares worth $477K. The position accounts for ﹤0.01% of the portfolio, ranked #4584.

Raymond James Financial first reported a position in EPRX in Q4 2024 and has held it in 8 quarters since. 35 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

Raymond James Financial held 52,439 shares of Eupraxia Pharmaceuticals worth $477K as of Q3 2026.
Raymond James Financial sold 1,064 Eupraxia Pharmaceuticals shares in Q3 2026, an estimated $7.57K.
Eupraxia Pharmaceuticals made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #4584 holding.
Raymond James Financial first reported a position in Eupraxia Pharmaceuticals in Q4 2024 and has held it in 8 quarters since.
35 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.